Simone Huygens
Overview
Explore the profile of Simone Huygens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Klein P, Huygens S, Handels R, Wester V, Kanters T
J Alzheimers Dis
. 2022 Jul;
89(1):359-366.
PMID: 35871348
Background: Disease modifying treatments (DMTs) currently under development for Alzheimer's disease, have the potential to prevent or postpone institutionalization and more expensive care and might delay institutionalization of persons with...
12.
Bosma F, Wijsman S, Huygens S, Passon-Vastenburg M
Acta Vet Scand
. 2022 Jul;
64(1):15.
PMID: 35804438
Background: The dimensions of the prostatic gland in castrated adult dogs, as assessed by ultrasonography, is currently not yet reported in veterinary literature. The current study was aimed at reporting...
13.
Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Rutten-van Molken M, et al.
Appl Health Econ Health Policy
. 2022 Apr;
20(4):501-524.
PMID: 35368231
Background: The number of healthcare interventions described as 'personalised medicine' (PM) is increasing rapidly. As healthcare systems struggle to decide whether to fund PM innovations, it is unclear what models...
14.
Vellekoop H, Versteegh M, Huygens S, Corro Ramos I, Szilberhorn L, Zelei T, et al.
Value Health
. 2022 Mar;
25(8):1428-1438.
PMID: 35248467
Objectives: Amidst conflicting expectations about the benefits of personalized medicine (PM) and the potentially high implementation costs, we reviewed the available evidence on the cost-effectiveness of PM relative to non-PM....
15.
Huygens S, Versteegh M
Value Health
. 2021 Oct;
24(11):1612-1619.
PMID: 34711361
Objectives: Most patients with multiple sclerosis (MS) switch between disease-modifying therapies (DMTs) during their lifetime. Our aim was to develop an MS cost-utility model that takes treatment switching into account...
16.
Cloosterman S, Wijnands I, Huygens S, Wester V, Lam K, Strijbis E, et al.
Brain Sci
. 2021 Oct;
11(10).
PMID: 34679370
(1) : Monitoring of Multiple Sclerosis (MS) with eHealth interventions or digital biomarkers provides added value to the current care path. Evidence in the literature is currently scarce. MS sherpa...
17.
Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, et al.
Pharmacoeconomics
. 2021 Apr;
39(7):771-788.
PMID: 33860928
Objective: The objective of this study was to develop guidance contributing to improved consistency and quality in economic evaluations of personalised medicine (PM), given current ambiguity about how to measure...